These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2330815)

  • 1. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.
    Svennerholm L; Gottfries CG; Blennow K; Fredman P; Karlsson I; Månsson JE; Toffano G; Wallin A
    Acta Neurol Scand; 1990 Jan; 81(1):48-53. PubMed ID: 2330815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers.
    Rost KL; Brockmöller J; Weber W; Roots I
    Clin Pharmacol Ther; 1991 Aug; 50(2):141-9. PubMed ID: 1868675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of GM1 ganglioside following parenteral administration.
    Cornelli U; Panucci A; Zingali G; Kirschner G; Baggio C; Cogo R
    J Pharm Pharmacol; 1990 Oct; 42(10):708-11. PubMed ID: 1982143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.
    Augustinsson LE; Blennow K; Blomstrand C; Bråne G; Ekman R; Fredman P; Karlsson I; Kihlgren M; Lehmann W; Lekman A; Månsson JE; Ramström I; Wallin A; Wikkelsö C; Gottfries CG; Svennerholm L
    Dement Geriatr Cogn Disord; 1997; 8(1):26-33. PubMed ID: 8997549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms.
    Ala TA; Perfetti PA; Frey WH
    J Neuroimmunol; 1994 Aug; 53(1):109-13. PubMed ID: 8051293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme.
    Svennerholm L; Bråne G; Karlsson I; Lekman A; Ramström I; Wikkelsö C
    Dement Geriatr Cogn Disord; 2002; 14(3):128-36. PubMed ID: 12218255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of ganglioside GM1 in acute stroke.
    Hoffbrand BI; Bingley PJ; Oppenheimer SM; Sheldon CD
    J Neurol Neurosurg Psychiatry; 1988 Sep; 51(9):1213-4. PubMed ID: 3066849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of exogenous tritium-labelled GM1lactone in the rat.
    Bellato P; Milan F; Facchinetti E; Toffano G
    Neurochem Int; 1992 Apr; 20(3):359-64. PubMed ID: 1304330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganglioside GM1 in acute ischemic stroke. The SASS Trial.
    Stroke; 1994 Jun; 25(6):1141-8. PubMed ID: 8202971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease.
    Svennerholm L
    Life Sci; 1994; 55(25-26):2125-34. PubMed ID: 7997071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease.
    Huang M; Hu M; Song Q; Song H; Huang J; Gu X; Wang X; Chen J; Kang T; Feng X; Jiang D; Zheng G; Chen H; Gao X
    ACS Nano; 2015 Nov; 9(11):10801-16. PubMed ID: 26440073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to ganglioside GM1 in patients with Alzheimer's disease.
    Chapman J; Sela BA; Wertman E; Michaelson DM
    Neurosci Lett; 1988 Mar; 86(2):235-40. PubMed ID: 3368123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease is associated with disordered localization of ganglioside GM1 molecular species in the human dentate gyrus.
    Hirano-Sakamaki W; Sugiyama E; Hayasaka T; Ravid R; Setou M; Taki T
    FEBS Lett; 2015 Nov; 589(23):3611-6. PubMed ID: 26484596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
    Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
    Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siagoside. GM1, Sygen.
    Drugs R D; 1999 Jan; 1(1):36-7. PubMed ID: 10565981
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients.
    Pitto M; Raimondo F; Zoia C; Brighina L; Ferrarese C; Masserini M
    Neurobiol Aging; 2005 Jun; 26(6):833-8. PubMed ID: 15718041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives.
    Fusco M; Vantini G; Schiavo N; Zanotti A; Zanoni R; Facci L; Skaper SD
    Ann N Y Acad Sci; 1993 Sep; 695():314-7. PubMed ID: 8239303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of drugs for Alzheimer's disease.
    Parnetti L
    Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The metabolism of radiolabelled GM1-ganglioside in cultured skin fibroblasts from controls and patients with GM1-gangliosidosis].
    Inui K
    Nihon Rinsho; 1995 Dec; 53(12):3102-4. PubMed ID: 8577066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
    Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
    Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.